Quantumzyme Corp. (OTC: QTZM) participated in the Enzyme Engineering XXVIII Conference, held from September 15-19, 2025, in Helsingor, Denmark. Organized by Engineering Conferences International (ECI), the biennial event gathered global leaders in enzyme design, biocatalysis, and synthetic biology. Quantumzyme’s presence at this forum underscores its commitment to advancing computational biocatalysis and sustainable manufacturing.
The company presented its latest innovations in enzyme-driven synthesis of active pharmaceutical ingredients (APIs), notably its recently published ibuprofen patent (US20250146029A1). This patent details a novel enzymatic pathway for ibuprofen production, marking a significant milestone in eco-friendly pharmaceutical manufacturing. By leveraging enzyme-based processes, Quantumzyme aims to reduce waste and energy consumption compared to traditional chemical synthesis.
Naveen Kulkarni, CEO of Quantumzyme Corp., stated that participation in the conference provided a platform to share the company’s vision and engage with thought leaders. He noted that discussions and collaborations initiated during the event reinforce Quantumzyme’s mission to accelerate the adoption of sustainable biocatalytic solutions worldwide.
Quantumzyme’s proprietary QZyme Workbench™ platform integrates quantum mechanics, artificial intelligence, and molecular modeling to design next-generation enzymes for diverse industrial applications. The platform enables the engineering of high-performance biocatalysts that enhance efficiency, reduce waste, and minimize environmental impact. The company’s involvement in the conference reflects its growing reputation as a key innovator in green chemistry and computational enzyme design.
For more information about the conference, visit ECI Enzyme Engineering XXVIII. The company encourages stakeholders to visit its website at www.quantumzymecorp.com and its profile on www.otcmarkets.com/stock/QTZM for the most current information.
Quantumzyme Corp. is a biotransformation company that specializes in sustainable, enzyme-based solutions for chemical processes. By integrating computational modeling with wet-lab validation, the company delivers scalable, cost-effective biocatalysis solutions that improve industrial sustainability. Its end-to-end enzyme development services range from discovery and engineering to process optimization and scale-up, empowering partners to adopt greener production methods.
The company’s vision is a future where biotechnology drives global solutions for climate change, pollution, and resource efficiency, making eco-friendly biocatalysis the industry standard. Through its participation in events like Enzyme Engineering XXVIII, Quantumzyme continues to build collaborations that further its mission of accelerating the adoption of sustainable biocatalytic solutions.
